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viral response to interferon a2a and a2b in chronic hepatitis C
patients with advanced ﬁbrosis
Advanced hepatic ﬁbrosis is associated with a worse prognosis in
patients with chronic hepatitis C virus (HCV) infection. Cumula-
tive clinical experience also suggests that response rates to
anti-viral therapy with pegylated interferons a2a or a2b and
ribavirin are inversely proportional to the degree of ﬁbrosis.
The mechanism involved in the overall hyporesponsiveness to
anti-viral treatment in patients with advanced ﬁbrosis is not
completely understood. At present, it is not clear whether
advanced ﬁbrosis per se is a key factor in the reduced responsive-
ness to anti-viral therapy or whether the different conﬁguration
of the pegylated interferon molecules and their impact on various
genes expression play a role in this phenomenon. Among the var-
ious factors which have been implicated in failure of anti-viral
therapy in such patients (i.e. high BMI, older age, ethnic back-
ground, genotype, viral load, incomplete adherence to treatment
protocols, and cytopenia) it was postulated that the distorted
hepatic architecture in advanced ﬁbrosis prevents an optimal
access of anti-viral drugs to the HCV infected hepatocytes, but
proof for this hypothesis is still lacking. In this context, it was
suggested that variations in pharmacodynamics, volume of distri-
bution and pharmacokinetics between pegylated interferon a2a
and a2b may explain, at least in part, the reported differences
in obtaining an SVR by between the two agents [1,2].
In the present issue of the Journal, Prati and co-workers have
performed a sub-analysis of the original Italian MIST study data-
base, assessing the therapeutic response to the two different
pegylated interferons a2a and a2b combined with ribavirin,
administered to chronic hepatitis C patients with various degrees
of ﬁbrosis [1]. The 431 consecutively enrolled treatment naïve
patients (genotypes 1–4) were randomized to receive the recom-
mended licensed dose of pegylated interferons a2a or a2b (with
ribavirin) for a standard duration based on genotype. Patients
were stratiﬁed according to genotype and the Ishak classiﬁcation
into three main groups according to degree of ﬁbrosis on liver
biopsy: Mild ﬁbrosis S0–S2, moderate ﬁbrosis S3–S4 and cirrhosis
S5–S6. The main message of this analysis suggests that efﬁcacy of
treatment as determined by end of treatment (ETR) and sustained
viral response (SVR), is lower, (mainly in genotypes 1 and 4) inJournal of Hepatology 20
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interferon a2b and ribavirin as compared to treatment with
pegylated interferon a2a. This difference in efﬁcacy of the two
agents was limited to patients with advanced ﬁbrosis. The lower
rates of SVR in patients with cirrhosis treated with pegylated
interferon a2b correspond to the lower response rates at ETR.
The data also suggest that patients with cirrhosis treated by
pegylated interferon a2b who do not reach a rapid viral response
(RVR) are unlikely to reach an SVR and treatment should be dis-
continued. In contrast, about one third of patients with cirrhosis
treated by pegylated interferon a2a who did not reach an RVR,
still developed an SVR. Finally, the obtained results suggest and
conﬁrm that RVR is an independent factor in prediction of success
of treatment irrespective of stage of ﬁbrosis or pegylated inter-
feron used.
Comparative assessment of the anti-viral efﬁcacy of the two
licensed pegylated interferons in patients with or without
advanced ﬁbrosis has met so far with some difﬁculties for a num-
ber of reasons. These include among others, differences in dosing
of ribavirin as well as in the molecular size of the polyethylene
glycol moieties which in turn has an impact on the pharmacoki-
netic and pharmacodynamic properties of both interferons.
Results of an early industry initiated randomized comparative
trial (IDEAL study) in 3070 patients revealed overall similar rates
of SVR in genotype 1 patients with chronic HCV infection treated
either with pegylated interferon a2a or a2b [3]. One year later,
two groups in Italy reported higher overall rates of SVR in chronic
HCV patients treated with pegylated interferon a2a as compared
to a2b [1,2]. In these investigator initiated prospective head to
head trials across genotypes 1–4, about one ﬁfth had evidence
for progressive ﬁbrosis. A recent metanalysis of 12 randomized
clinical trials (N = 5008 patients), which compared treatment
with peginterferon a2a plus ribavirin to peginterferon a2b plus
ribavirin provided further support to the observations from Italy
[4]. Although the overall difference in SVR between the two pegy-
lated interferon reagents was only 6% (in eight trials), it was sta-
tistically signiﬁcant [4]. The results reported by Prati et al. suggest
that the difference in SVR rates between the two pegylated inter-
feron based protocols is mainly limited to patients with advanced
ﬁbrosis.
The discussed study has a number of limitations, most of
which are already acknowledged by the authors. These include
the fact that the original MIST study was not designed to examine
the degree and impact of ﬁbrosis on the efﬁcacy of the two
pegylated interferons. As a result, the size of the various
groups studied is relatively small and the study is somewhat12 vol. 56 j 303–304
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underpowered. This drawback is partially compensated for
by multivariate logistic regression analysis according to liver
ﬁbrosis. It is also not clear yet if the IL28B single nucleotide poly-
morphism, not included in the present analysis, has an impact on
response rates to anti-viral therapy in general and to speciﬁc
interferons in particular in HCV patients with advanced ﬁbrosis.
It is important to note that the new data presented in this anal-
ysis by Prati et al. still do not provide a clue to explain the mech-
anism responsible for the different response rates to treatment
with the two interferon molecules. Finally, one should remember
that it remains to be seen if the introduction of new directly act-
ing anti-viral agents (DAAs), will blur the observed differences in
anti-viral efﬁcacy between the two interferon molecules in
patients with advanced ﬁbrosis. The investigators of this study
conclude that chronic HCV patients infected with genotypes 1/4
with advanced ﬁbrosis are more likely to beneﬁt from treatment
with pegylated interferon a2a and ribavirin as compared to inter-
feron a2b. This may indeed be the case, yet further conﬁrmation
of this statement is warranted in view of the fact that these data
were obtained through subanalysis of a prospective trial which
was not originally designed to address this question.304 Journal of Hepatology 201Conﬂict of interest
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